{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-180820","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.903066+00:00","generated_at":"2026-05-17T13:02:01.067654+00:00","sec_items":["2.02","4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results","bullets":["Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.","Identified a material weakness in internal control over financial reporting related to accounting for equity instruments; controls and disclosure controls were not effective.","Reported Q2 2025 net loss of $11.2 million ($0.13 per share) and cash and short-term investments of $107.6 million as of June 30, 2025.","Updated Phase 1b data for tegoprubart showed mean 12-month eGFR of ~68 mL/min/1.73m²; Phase 2 BESTOW topline expected November 2025.","Company expects current cash to fund operations to the end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-180820","json":"https://secwatch.observer/filing/0001193125-25-180820.json","markdown":"https://secwatch.observer/filing/0001193125-25-180820.md","text":"https://secwatch.observer/filing/0001193125-25-180820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/0001193125-25-180820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T13:02:01.067654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}